Skip to main content
Premium Trial:

Request an Annual Quote

Extending Deal, Lynx and Aventis CropScience Will Co-Develop Plant Assays

NEW YORK, April 1 - Lynx Therapeutics and Aventis CropScience will co-develop and commercialize an assay based on Lynx's bead-based technologies, the companies said today.
 
Terms of the collaboration, which extends by five years a deal the firms inked in March 1999 that gave the German ag-bio firm access to Lynx's genomics-discovery services, will give the companies joint ownership of the assay technology.

Lynx will manufacture and sell the services or products and will pay related royalties to Frankfurt-based Aventis CropScience. Lynx, of Hayward, Calif., will be paid for "performing genomics-discovery services" for Aventis CropScience during the deal's development and commercialization stage.

Further financial details of the agreement were not disclosed.

"We believe that initial results suggest that the use of our quantitative technologies will provide an excellent method for the development of effective assays for use in crops," Norrie Russell, president and CEO of Lynx, said in a statement. "We are excited about the extension of our agreement with Aventis CropScience, and we look forward to the commercialization of the assays."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.